GT201300307A - "derivados de pirazol útiles como inhibidores de aldosterona sintasa" - Google Patents

"derivados de pirazol útiles como inhibidores de aldosterona sintasa"

Info

Publication number
GT201300307A
GT201300307A GT201300307A GT201300307A GT201300307A GT 201300307 A GT201300307 A GT 201300307A GT 201300307 A GT201300307 A GT 201300307A GT 201300307 A GT201300307 A GT 201300307A GT 201300307 A GT201300307 A GT 201300307A
Authority
GT
Guatemala
Prior art keywords
sintasa
inhibitors
aldosterona
useful
pirazol
Prior art date
Application number
GT201300307A
Other languages
English (en)
Spanish (es)
Inventor
Michael Gregory Bell
Ana Maria Escribano
Paul J Hoogestraat
Thomas Edward Mabry
Quanrong Shen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GT201300307A publication Critical patent/GT201300307A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GT201300307A 2011-06-14 2013-12-11 "derivados de pirazol útiles como inhibidores de aldosterona sintasa" GT201300307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496657P 2011-06-14 2011-06-14
US201161506349P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
GT201300307A true GT201300307A (es) 2014-11-24

Family

ID=46317515

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300307A GT201300307A (es) 2011-06-14 2013-12-11 "derivados de pirazol útiles como inhibidores de aldosterona sintasa"

Country Status (33)

Country Link
US (1) US8778984B2 (enExample)
EP (1) EP2721009B1 (enExample)
JP (1) JP5890012B2 (enExample)
KR (1) KR101555119B1 (enExample)
CN (1) CN103596930B (enExample)
AR (1) AR086665A1 (enExample)
AU (1) AU2012271023A1 (enExample)
BR (1) BR112013031873A2 (enExample)
CA (1) CA2836804C (enExample)
CL (1) CL2013003536A1 (enExample)
CO (1) CO6821955A2 (enExample)
CR (1) CR20130601A (enExample)
CY (1) CY1116687T1 (enExample)
DK (1) DK2721009T3 (enExample)
DO (1) DOP2013000284A (enExample)
EA (1) EA201391655A1 (enExample)
EC (1) ECSP13013080A (enExample)
ES (1) ES2548210T3 (enExample)
GT (1) GT201300307A (enExample)
HR (1) HRP20150939T1 (enExample)
HU (1) HUE026461T2 (enExample)
IL (1) IL229485A0 (enExample)
ME (1) ME02223B (enExample)
MX (1) MX336042B (enExample)
PE (1) PE20140606A1 (enExample)
PH (1) PH12013502597A1 (enExample)
PL (1) PL2721009T3 (enExample)
PT (1) PT2721009E (enExample)
RS (1) RS54269B1 (enExample)
SG (1) SG194822A1 (enExample)
SI (1) SI2721009T1 (enExample)
TW (1) TWI518073B (enExample)
WO (1) WO2012173849A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016002918A1 (ja) * 2014-07-04 2016-01-07 日本たばこ産業株式会社 インドール化合物の製造方法
CN108586221B (zh) * 2018-06-26 2021-03-02 常州制药厂有限公司 用于制备替卡格雷的中间体及其制备方法
CN112409432B (zh) * 2020-11-16 2023-07-07 陕西理工大学 一种依西美坦的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57165369A (en) * 1981-04-06 1982-10-12 Teijin Ltd Pyrazole derivative and its preparation
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
JPWO2007111175A1 (ja) 2006-03-17 2009-08-13 日本碍子株式会社 目封止ハニカム構造体の製造方法
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
PL2523731T3 (pl) 2010-01-14 2019-04-30 Novartis Ag Zastosowanie środka modyfikującego hormon nadnerczy

Also Published As

Publication number Publication date
PE20140606A1 (es) 2014-05-17
MX336042B (es) 2016-01-07
US8778984B2 (en) 2014-07-15
EP2721009A1 (en) 2014-04-23
ECSP13013080A (es) 2014-01-31
MX2013014790A (es) 2014-01-24
EA201391655A1 (ru) 2014-07-30
SI2721009T1 (sl) 2015-10-30
HK1193103A1 (en) 2014-09-12
HUE026461T2 (en) 2016-05-30
TW201311647A (zh) 2013-03-16
HRP20150939T1 (xx) 2015-10-09
CY1116687T1 (el) 2017-03-15
CO6821955A2 (es) 2013-12-31
SG194822A1 (en) 2013-12-30
CA2836804A1 (en) 2012-12-20
BR112013031873A2 (pt) 2016-12-13
US20120322841A1 (en) 2012-12-20
DK2721009T3 (en) 2015-10-26
CN103596930B (zh) 2015-05-13
JP5890012B2 (ja) 2016-03-22
CN103596930A (zh) 2014-02-19
WO2012173849A1 (en) 2012-12-20
EP2721009B1 (en) 2015-08-12
IL229485A0 (en) 2014-01-30
ES2548210T3 (es) 2015-10-14
PL2721009T3 (pl) 2016-01-29
RS54269B1 (sr) 2016-02-29
KR101555119B1 (ko) 2015-09-22
KR20140009564A (ko) 2014-01-22
PT2721009E (pt) 2015-10-23
AR086665A1 (es) 2014-01-15
TWI518073B (zh) 2016-01-21
NZ617642A (en) 2015-11-27
AU2012271023A1 (en) 2013-11-28
CR20130601A (es) 2014-05-02
CA2836804C (en) 2016-05-24
JP2014517034A (ja) 2014-07-17
CL2013003536A1 (es) 2014-07-11
PH12013502597A1 (en) 2018-04-11
DOP2013000284A (es) 2014-06-30
ME02223B (me) 2016-02-20

Similar Documents

Publication Publication Date Title
ECSP12011581A (es) Inhibidores de bace
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
UA114476C2 (uk) Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
MX347038B (es) Proteínas de membrana solubles en agua y métodos para la preparación y uso de las mismas.
GT201400017A (es) Derivados de piridin-2 (1h) -ona como inhibidores de jak
GT201400127A (es) Anticuerpos anti-phf-tau y sus usos
EA201390203A1 (ru) Способы получения тубулизинов
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
MX2021001231A (es) Compuestos heterociclicos y sus usos.
EA201270722A1 (ru) Формы рифаксимина и их применение
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay
BR112014006482A2 (pt) uso de derivados de isossorbida para produção de preparações cosméticas
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CO7091179A2 (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
CO6970609A2 (es) Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona
MX347855B (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201400444A1 (ru) Производные 2-оксопиперидинила
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas
GT201300307A (es) "derivados de pirazol útiles como inhibidores de aldosterona sintasa"
EA201492280A1 (ru) Стабильный состав пексиганана
GT201300003A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion , y las composiciones farmacèuticas que la contienen
BR112013025236A2 (pt) derivados de tieno [2,3-d)pirimidina e seu uso no tratamento de arritmia
IT1400964B1 (it) Procedimento per la preparazione di derivati pteridinici